En Es
Categories

Industry News

Qiagen Acquires Bioinformatics Firm OmicSoft

By Labmedica International staff writers
12 Jan 2017

Image: QIAGEN has acquired OmicSoft, a bioinformatics company (Photo courtesy of iStock).QIAGEN N.V. (Hilden, Germany), a provider of sample and assay technologies, has acquired OmicSoft Corporation (Cary, NC, USA), which focuses on biomarker data management, visualization, and analysis.

QIAGEN’s broad range of consumables includes complete kits for predefined applications in sample preparation and analysis and also individual enzymes and reagents that research laboratories can use to develop their own applications. QIAGEN also offers instruments for automating the full range of laboratory procedures, from the initial sample preparation to the final test result. Its solutions find applications in human healthcare, forensics, veterinary testing, food safety, pharma and biotech companies, and life sciences research.

OmicSoft designs and develops bioinformatics, next generation sequencing, and cancer genomics software for biomarker data management, visualization, and analysis. Its suite of software solutions enable scientists and researchers to efficiently analyze and visualize their own data sets and compare them to massive volumes of publicly available ‘omics’ data sets, and share the results with colleagues.

The acquisition will provide QIAGEN access to OmicSoft’s multi-omics data management infrastructure solution as well as curated ‘omics’ data sets that complement its bioinformatics portfolio for gaining insights into complex biological data. With the addition of OmicSoft, QIAGEN will be able to offer solutions across the full spectrum of data management and interpretation needs.

“The addition of OmicSoft to QIAGEN’s portfolio of Sample to Insight solutions reinforces our position as the gold standard for analysis and interpretation of complex biological data across many different disciplines,” said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.
“The OmicSoft team has deep expertise that will enable QIAGEN to better support customers in managing vast data sets and gaining actionable insights for discovery and translational research,” said Dr. Laura Furmanski, Senior Vice President and Head of the Bioinformatics Business Area at QIAGEN. “The market opportunity is significant given the expanding use of multiple ‘omics’ data in research and clinical healthcare. We intend to integrate the OmicSoft solutions into our full bioinformatics interpretation portfolio, and make it a key differentiator in our Sample to Insight offerings.”

Related Links
QIAGEN
OmicSoft



E-mail Print
FaceBook Twitter Google+ Linked in

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including complete kits for pre-defined applications in sample preparation and analysis, and individual enzymes and reagents. It also offers instruments for automating the full range of laboratory procedures, from the initial sample preparation to the final test result.
More info

More articles about QIAGEN

02 Jul 2021
Qiagen Partners with Sysmex for Development and Commercialization of Cancer Companion Diagnostics
QIAGEN N.V. (Venlo, Netherlands) and Sysmex Corporation (Kobe, Japan) have entered into a global strategic alliance for the development and commercialization of cancer companion diagnostics, which will leverage both QIAGEN’s leadership in this field and Sysmex’s Plasma-Safe-SeqS technology for next generation sequencing (NGS).
Read More
14 Aug 2020
QIAGEN to Focus on Molecular Testing amidst Coronavirus Pandemic after Voluntary Public Takeover Offer by Thermo Fisher Falls Short
QIAGEN N.V. (Venlo, Netherlands) plans to continue executing its growth strategy aimed at creating significant value for shareholders and other stakeholders after the voluntary public takeover offer by Thermo Fisher Scientific Inc. (Waltham, MA, USA) failed to achieve the minimum 66.67% acceptance threshold from QIAGEN shareholders.
Read More
13 Feb 2018
QIAGEN Enters into Agreement to Acquire STAT-Dx
QIAGEN N.V. has entered into an agreement to acquire STAT-Dx, a privately-held company which develops next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.
Read More

Additional news

25 Nov 2021
Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases
The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic cases, technological developments in point of care devices and increased investments by the key players.
Read More
24 Nov 2021
Euromedlab Congress 2021 Postponed as Fourth COVID-19 Wave Hits Germany
The XXIV IFCCEFLM European Congress of Clinical Chemistry and Laboratory Medicine (EuroMedLab Congress 2021) to be held as an in-presence meeting between 28th of November and 2nd of December in Germany has been postponed as the country has been hit very hard by a fourth wave of COVID-19.
Read More
19 Nov 2021
44th World Hospital Congress (WHC) Ends on Upbeat Note as Hospital Leaders Look to Build Resilience
The 44th World Hospital Congress (WHC) organized by The International Hospital Federation (IHF; Geneva, Switzerland) on 8-11 November 2021 in Barcelona, Spain came to an upbeat close.
Read More
16 Nov 2021
Deborah Bowen (USA) Takes Up Position of IHF President for 2021-2023
Deborah Bowen has taken up the position of President of the International Hospital Federation (IHF; Geneva, Switzerland) following her election in 2019 and a two-year term as President Designate.
Read More
16 Nov 2021
IHF and Deloitte Collaborate to Launch Special Interest Group on Leadership for Sustainability
The International Hospital Federation (IHF; Geneva, Switzerland) will collaborate with Deloitte (London, UK) to launch a special interest group (SIG) centered around leadership for sustainability.
Read More
16 Nov 2021
International Hospital Federation (IHF) Announces Winners of IHF Awards 2021
The International Hospital Federation (IHF; Geneva, Switzerland) announced the winners of the IHF Awards 2021 as part of a special ceremony at the 44th World Hospital Congress (WHC) held in Barcelona, Spain.
Read More
13 Nov 2021
GE Healthcare to be Spun Off in 2023 to Create Pure-Play Company at Center of Precision Health
General Electric (GE; Boston, MA, USA) plans to pursue a tax-free spin-off of GE Healthcare, creating a pure-play company at the center of precision health in early 2023.
Read More
11 Nov 2021
Blood Borne Testing Market to Witness Exponential Growth Due to Rising Incidence of Bacterial Infections
The global blood borne testing market is projected to record an exponential CAGR of over 7-8% during 2021-2031, driven by increasing bacterial infection and growing adoption of point of care devices, aided further by technological advancement in devices for blood borne pathogens. These are the latest findings of Fact.MR (Dublin, Ireland), a market research firm.
Read More
10 Nov 2021
AI in Radiology Market Driven by Growing Adoption of Machine Learning Tools in Broad Spectrum of Imaging Applications
The use of AI algorithms in medical image analysis field has made astounding progress. Particularly deep learning has made incessant inroads in radiology practice. The major consumer proposition for companies in the AI in radiology market stems from the exceptional capabilities of AI tools in recognizing complex patterns in the imaging data. These are the latest findings of Transparency Market Research (Albany NY, USA).
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions